Ausgabe 6/2020
Inhalt (31 Artikel)
Tivantinib inhibits the VEGF signaling pathway and induces apoptosis in gastric cancer cells with c-MET or VEGFA amplification
Bum Jun Kim, Yoo Jin Kim, Sung-Hwa Sohn, Bohyun Kim, Hee Jung Sul, Hyeong Su Kim, Dae Young Zang
The near-infrared fluorescent dye IR-780 was coupled with cabazitaxel for castration-resistant prostate cancer imaging and therapy
Yu Zheng, Guangdong Hou, Geng Zhang, Ting Lan, Jiarui Yuan, Lei Zhang, Fei Yan, Fuli Wang, Ping Meng, Xinlong Dun, Xi’an Li, Guo Chen, Zheng Zhu, Di Wei, Wei He, Jianlin Yuan
CPBMF65, a synthetic human uridine phosphorylase-1 inhibitor, reduces HepG2 cell proliferation through cell cycle arrest and senescence
Elisa Feller Gonçalves da Silva, Kelly Goulart Lima, Gabriele Catyana Krause, Gabriela Viegas Haute, Leonardo Pedrazza, Anderson Velasque Catarina, Rodrigo Benedetti Gassen, Bruno de Souza Basso, Henrique Bregolin Dias, Carolina Luft, Maria Claudia Rosa Garcia, Bruna Pasqualotto Costa, Géssica Luana Antunes, Luiz Augusto Basso, Márcio Vinícius Fagundes Donadio, Pablo Machado, Jarbas Rodrigues de Oliveira
The pan-Bcl-2 inhibitor obatoclax promotes differentiation and apoptosis of acute myeloid leukemia cells
Małgorzata Opydo-Chanek, Iwona Cichoń, Agnieszka Rak, Elżbieta Kołaczkowska, Lidia Mazur
Mechanisms of Efficacy of the FGFR1–3 Inhibitor AZD4547 in Pediatric Solid Tumor Models
Nikki Phanhthilath, Sara Hakim, Catherine Su, Andrea Liu, Divya Subramonian, Jacqueline Lesperance, Peter E. Zage
ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib
Sho Sakamoto, Kazuhiro Sato, Yuri Takita, Yuka Izumiya, Naho Kumagai, Kazuhisa Sudo, Yukiyasu Hasegawa, Hayato Yokota, Yumiko Akamine, Yuji Okuda, Mariko Asano, Masahide Takeda, Masaaki Sano, Masatomo Miura, Katsutoshi Nakayama
Chemosensitivity to HM90822, a novel synthetic IAP antagonist, is determined by p-AKT-inducible XIAP phosphorylation in human pancreatic cancer cells
Seung-Woo Hong, Jae-Sik Shin, Jai-Hee Moon, Soo-A Jung, Dong-In Koh, Yeaseong Ryu, Yoon Sun Park, Do Yeon Kim, Sang-Soo Park, Jun Ki Hong, Eun Ho Kim, Mi Jin Kim, Hong-Rae Jeong, In Hwan Bae, Young-Gil Ahn, Kwee Hyun Suh, Ig-Jun Cho, Jong-Soon Kang, Yong Sang Hong, Jung Shin Lee, Dong-Hoon Jin, Tae Won Kim
Ubiquitin-specific protease 7 is a druggable target that is essential for pancreatic cancer growth and chemoresistance
Hao Chen, Xiaoling Zhu, Rong Sun, Panpan Ma, Erhao Zhang, Zhou Wang, Yihui Fan, Guoxiong Zhou, Renfang Mao
Integrative analysis of key candidate genes and signaling pathways in autoimmune thyroid dysfunction related to anti-CTLA-4 therapy by bioinformatics
Ying Zhang, Francesca Garofano, Xiaolong Wu, Matthias Schmid, Peter Krawitz, Markus Essler, Ingo G. H. Schmidt-Wolf
The kinesin motor protein KIF4A as a potential therapeutic target in renal cell carcinoma
Guihong Liu, Yachun Lu, Liantao Li, Tao Jiang, Sufang Chu, Pingfu Hou, Jin Bai, Ming Chen
Glioma progression is suppressed by Naringenin and APO2L combination therapy via the activation of apoptosis in vitro and in vivo
Tao Song, Mingyu Zhang, Jun Wu, Fenghua Chen, Ying Wang, Yujie Ma, Zhijie Dai
A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors
Mojun Zhu, Julian R. Molina, Grace K. Dy, Gary A. Croghan, Yingwei Qi, James Glockner, Lorelei J. Hanson, Michelle M. Roos, Angelina D. Tan, Alex A. Adjei
Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors
Jaffer A. Ajani, Milind Javle, Cathy Eng, David Fogelman, Jackie Smith, Barry Anderson, Chun Zhang, Kenzo Iizuka
A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment
Jean-Pierre Delord, Guillem Argilés, Jerôme Fayette, Lori Wirth, Stefan Kasper, Salvatore Siena, Ricard Mesia, Rossana Berardi, Andrés Cervantes, Jeroen Dekervel, Sylvia Zhao, Yongjian Sun, Huai-Xiang Hao, Ralph Tiedt, Sergio Vicente, Andrea Myers, Lillian L. Siu
A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma
David A. Reardon, Annick Desjardins, Olivier Rixe, Timothy Cloughesy, Shilpa Alekar, Jason H. Williams, Ray Li, Carrie Turich Taylor, Andrew B. Lassman
Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation
Philippe B. Pierrillas, Emilie Henin, Julien Ogier, Magali Amiel, Laurence Kraus-Berthier, Marylore Chenel, François Bouzom, Michel Tod
Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma
Bradley A. McGregor, Michael Gordon, Ronan Flippot, Neeraj Agarwal, Saby George, David I. Quinn, Mark Rogalski, Thomas Hawthorne, Tibor Keler, Toni K. Choueiri
A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors
Charlotte Lemech, Natasha Woodward, Nancy Chan, Joanne Mortimer, Louie Naumovski, Silpa Nuthalapati, Bo Tong, Fang Jiang, Peter Ansell, Christine K. Ratajczak, Jasgit Sachdev
First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects
Meng-na Wang, Yun Kuang, Li-ying Gong, Ye Hua, Qi Pei, Cheng-xian Guo, Yu Cao, Jie Huang, Guo-ping Yang
Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer
Shunsuke Kondo, Masaomi Tajimi, Tomohiko Funai, Koichi Inoue, Hiroya Asou, Vinay Kumar Ranka, Volker Wacheck, Toshihiko Doi
Correction to: Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer
Shunsuke Kondo, Masaomi Tajimi, Tomohiko Funai, Koichi Inoue, Hiroya Asou, Vinay Kumar Ranka, Volker Wacheck, Toshihiko Doi
Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study
Ling Li, Fei Kong, Lei Zhang, Xin Li, Xiaorui Fu, Xinhua Wang, Jingjing Wu, Fangwen Zhang, Liangliang Ren, Mingzhi Zhang
Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial
Kazuhisa Nakashima, Yuichi Ozawa, Haruko Daga, Hisao Imai, Motohiro Tamiya, Takaaki Tokito, Takahisa Kawamura, Hiroaki Akamatsu, Yuko Tsuboguchi, Toshiaki Takahashi, Nobuyuki Yamamoto, Keita Mori, Haruyasu Murakami
A randomized, double-blind, placebo-controlled study of B-cell lymphoma 2 homology 3 mimetic gossypol combined with docetaxel and cisplatin for advanced non-small cell lung cancer with high expression of apurinic/apyrimidinic endonuclease 1
Yuxiao Wang, Xuemei Li, Liang Zhang, Mengxia Li, Nan Dai, Hao Luo, Jinlu Shan, Xueqin Yang, Mingfang Xu, Yan Feng, Chengxiong Xu, Chengyuan Qian, Dong Wang
Mitomycin C plus cisplatin for systemic treatment of recurrent BRCA1-associated ovarian cancer
Tatyana V. Gorodnova, Anna P. Sokolenko, Sergey V. Kondratiev, Khristina B. Kotiv, Alexey M. Belyaev, Igor V. Berlev, Evgeny N. Imyanitov
Modernizing adverse events analysis in oncology clinical trials using alternative approaches: rationale and design of the MOTIVATE trial
Bastien Cabarrou, Carlos Gomez-Roca, Marie Viala, Audrey Rabeau, Rodolphe Paulon, Delphine Loirat, Nadia Munsch, Jean-Pierre Delord, Thomas Filleron
The old CEACAMs find their new role in tumor immunotherapy
Zi-Wen Han, Zhi-Wu Lyv, Bin Cui, Ying-Ying Wang, Jun-Ting Cheng, Ying Zhang, Wen-Qi Cai, Yang Zhou, Zhao-Wu Ma, Xian-Wang Wang, Xiao-Chun Peng, Shu-Zhong Cui, Ying Xiang, Mo Yang, Hong-Wu Xin
Correction to: The old CEACAMs find their new role in tumor immunotherapy
Zi-Wen Han, Zhi-Wu Lyv, Bin Cui, Ying-Ying Wang, Jun-Ting Cheng, Ying Zhang, Wen-Qi Cai, Yang Zhou, Zhao-Wu Ma, Xian-Wang Wang, Xiao-Chun Peng, Shu-Zhong Cui, Ying Xiang, Mo Yang, Hong-Wu Xin
Early-onset meningitis associated with atezolizumab treatment for non-small cell lung cancer: case report and literature review
Koichi Ogawa, Hiroyasu Kaneda, Tamaki Kawamoto, Yoko Tani, Motohiro Izumi, Yoshiya Matsumoto, Kenji Sawa, Tomohiro Suzumura, Tetsuya Watanabe, Shigeki Mitsuoka, Kazuhisa Asai, Tomoya Kawaguchi
Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer
Satoshi Igawa, Taihei Ono, Masashi Kasajima, Seiichiro Kusuhara, Sakiko Otani, Tomoya Fukui, Masanori Yokoba, Masaru Kubota, Masato Katagiri, Hisashi Mitsufuji, Jiichiro Sasaki, Katsuhiko Naoki
Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study
Shingo Nasu, Hidekazu Suzuki, Takayuki Shiroyama, Ayako Tanaka, Yumiko Samejima, Tomohiro Kanai, Yoshimi Noda, Naoko Morishita, Norio Okamoto, Tomonori Hirashima